Christopher Rovaldi - Feb 16, 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Operating Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Feb 16, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 03:19 PM
Previous filing
Apr 8, 2022
Next filing
Feb 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Award $0 +100K $0.00 100K Feb 16, 2023 Common Stock 100K $54.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.